Recently, the extracellular plasminogen activator inhibitor type I (PAI-1) was found to be responsible for internalizing PD-L1, and targeting PAI-1 with a pharmacological inhibitor (tiplaxtinin) has led to increased PD-L1 expression on tumor cells in vivo and in vitro. The gene discussed is SERPINE1; the disease is neoplasm.